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Platelet activation is increased in peripheral arterial
disease
K. Cassar, MD, FRCS(Ed),a P. Bachoo, FRCS(Gen Surg),c I. Ford, PhD,c M. Greaves, MD, FRCP,
FRCPath,b and J. Brittenden, MD, FRCS(Gen Surg),a Aberdeen, Scotland
Objective: Platelet activation was assessed in patients with peripheral arterial disease compared with healthy control
subjects.
Methods: This prospective comparative study included 100 subjects: 40 consecutive patients with intermittent claudica-
tion, 20 consecutive patients with critical ischemia and tissue loss, and 40 healthy control subjects. Whole blood flow
cytometric analysis was performed to determine resting and stimulated platelet P-selectin expression and resting and
stimulated platelet fibrinogen binding. Results are presented as platelet percentage and also as mean fluorescence
intensity.
Results: P-selectin expression was significantly increased in patients with intermittent claudication (median, 0.85%; range,
0.31%-4.77%; P  .023) and critical ischemia (median, 1.11%; range, 0.2%-3.26%; P  .028) compared with control
subjects (median, 0.59%; range, 0.16%-4.58%). The percentage of platelets binding fibrinogen was also significantly
higher in patients with intermittent claudication (median, 2.89%; range, 1.08%-9.59%; P < .001) compared with control
subjects (median, 1.57%; range, 0.17%-10.7%). There was no significant difference in percentage of platelet fibrinogen
binding between control subjects and patients with critical ischemia. Fibrinogen binding by stimulated platelets was
significantly diminished in patients with critical limb ischemia compared with control subjects (67.2% vs 77.9%; P 
.006).
Conclusions: Platelet activation is increased in patients with peripheral arterial disease, suggesting an underlying
prothrombotic state. Platelets from patients with critical limb ischemia are less responsive to in vitro stimulation. (J Vasc
Surg 2003;38:99-103.)
Patients with peripheral arterial disease (PAD) are at
significantly increased risk for cardiovascular and cerebro-
vascular events. Mortality from cardiovascular disease is two
to three times higher in patients with intermittent claudi-
cation compared with an age-matched and sex-matched
population.1 In the Edinburgh Artery Study almost 20% of
patients with intermittent claudication were dead within 5
years,2 13.7% from cardiovascular causes. In 1998 the Joint
British Recommendations on Prevention of Coronary
Heart Disease in Clinical Practice stated that patients with
peripheral vascular disease were “just as likely to die from a
heart attack as many patients who have survived their first
myocardial infarction” and recommended that treatment
should be the same as for patients with established coronary
heart disease.3 Abnormal platelet function has been impli-
cated in development and progression of atherosclerosis
and in pathogenesis of acute ischemic events. However,
although abnormalities in both coagulation and fibrinolysis
have been convincingly demonstrated in patients with
PAD,4-8 the role of platelet activation in this patient group
remains controversial.
Whole blood flow cytometry has emerged as a supe-
rior tool for investigation of platelet function and in vivo
platelet activation, mainly because, unlike platelet aggre-
gometry and plasma assays, it does not involve artifactual
platelet stimulation with centrifugation and stirring.9-11
However, the two major articles published on flow cyto-
metric assessment of platelet function with P-selectin
expression in patients with PAD yielded conflicting re-
sults.12,13
P-selectin is a granule membrane glycoprotein (Gp)
that in resting platelets is found in the membrane of alpha
granules.14 After platelet stimulation, a release reaction
from the granules occurs, and P-selectin is transferred to
the plasma membrane through membrane fusion.15
A P-selectin–specific monoclonal antibody binds only
to activated degranulated platelets. By binding a fluoro-
chrome dye to this antibody, flow cytometric analysis can
enable identification of those platelets in the population
that are activated.
Platelet activation also causes transformation of the
surface GpIIb/IIIa from an inactive to an active state,
which enables ligand binding.16-18 Through distinct amino
acid sequences, fibrinogen is bound to GpIIb/IIIa.19 With
a labeled specific anti-fibrinogen antibody, platelet fibrino-
gen binding can be reliably measured with flow cytom-
etry20 as a marker of platelet activation.
The goal of this study was to determine whether plate-
let activation is increased in patients with PAD compared
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with control subjects, with flow cytometric assessment of
P-selectin expression and fibrinogen binding.
METHODS
Subject selection. Participants in the study were re-
cruited from patients referred to the Vascular Unit, Aber-
deen Royal Infirmary. Patients were eligible for inclusion if
they had symptoms of intermittent calf claudication or
critical limb ischemia with tissue loss and supportive find-
ings at clinical examination and noninvasive laboratory
investigations of peripheral vascular disease. Exclusion cri-
teria included hemoglobin concentration less than 100
g/L; platelet count less than 150  109/L; creatinine
concentration more than twice the upper limit of normal;
aspartate aminotransferase, alkaline phosphatase, or -glu-
tamyl transferase concentration more than three times the
upper limit of normal; and body mass index exceeding 33.
In addition, patients with a history of hematologic malig-
nancy, acute illness unrelated to PAD within 14 days,
transfusion of whole blood within 14 days, known or
suspected alcohol or drug abuse, or receiving warfarin
sodium, steroid, or clopidogrel therapy were excluded.
Patients with diabetes were excluded from the claudication
group. Forty patients with intermittent calf claudication
and 20 patients with tissue loss were identified and re-
cruited for the study. All patients with intermittent claudi-
cation and critical ischemia were using aspirin when their
blood was sampled.
Healthy control subjects were recruited from patients
referred to the Vascular clinic with varicose veins but no
history of ischemic heart disease, cerebrovascular disease, or
peripheral vascular disease. All control subjects had a nor-
mal ankle-brachial pressure index (ABI). Forty control
subjects were identified and recruited for the study. None
of the control subjects were using aspirin.
Informed consent was obtained from each subject, and
full ethical approval for the study was sought and granted
by the Grampian Research Ethics Committee.
Sample preparation and flow cytometry. Blood
samples were collected with a 21-gauge needle inserted
into an antecubital vein, with the cuff applied to the upper
arm. The cuff was removed when the first trickle of blood
appeared in the first of two 1:10 3.2% sodium citrate
Vacutainers. For measurement of platelet activation, 50 L
of blood was immediately transferred from the second
sodium citrate container with a micropipet and diluted in
450 L of HEPES (N-2-hydroxyethylpiperazine-N-2-eth-
anesulfonic acid) magnesium buffer (10 mmol/L of
HEPES, 145 mmol/L of sodium chloride, 5 mmol/L of
potassium chloride, 1 mmol/L of magnesium sulfate, pH
7.4), and thus blood used for flow cytometry was taken
without a cuff.
The method of analysis was adapted from that de-
scribed previously.20 Samples were treated in a standard
manner within 1 hour of collection, as follows: 40 L
aliquots of whole blood in HEPES magnesium buffer were
incubated with monoclonal antibodies for 20 minutes at
room temperature in the dark. Platelets were labeled with
fluorescein isothiocyanate (FITC)–conjugated anti-CD61
(Dako, Glostrup, Denmark), which binds to GpIIIa. P-
selectin expression was measured with dual staining with
FITC–anti-CD61 and phycoerythrin (PE)–conjugated an-
ti-CD62P (Immunotech, Marseilles, France). Fibrinogen
binding was measured with single-color flow cytometry
with FITC-conjugated rabbit polyclonal anti-human fi-
brinogen antibody (Dako). An optimal final concentration
of 2 ng/L of each antibody was used. Reactions were
stopped with addition of 1 mL of phosphate-buffered saline
solution. Samples were analyzed within 4 hours of prepa-
ration with a Coulter XL-MCL flow cytometer (Coulter
Electronics, Luton, England). Platelets were gated by their
side and forward light scatter characteristics and enclosed in
an electronic bitmap. Listmode data were stored and pro-
cessed with a personal computer and SYSTEM II software
version 1.0 (Coulter Electronics), and converted to scatter-
plots and histograms. Ten thousand events were analyzed
for fluorescence, and the results were expressed as percent-
age of platelets positive for P-selectin and binding of fibrin-
ogen. Mean cell fluorescence as a measure of the average
density of antibody binding per platelet was recorded. Basal
activation status was assessed in resting samples and platelet
reactivity after incubation with adenosine diphosphate
(ADP) at a final concentration of 1  105 mol/L for 5
minutes (Sigma, St Louis, Mo). The flow cytometer was
aligned daily with Flowcheck and Immunobrite beads
(Coulter Electronics) to calibrate light scatter and fluores-
cence parameters, respectively. The flow cell was cleaned
thoroughly between individual subject samples to exclude
carryover of platelets to subsequent analyses with Coulter
Clenz cleansing solution (Coulter Electronics). Murine
FITC-conjugated and PE-conjugated isotype controls
(Becton Dickinson, Oakville, Canada,) were used to adjust
for nonspecific antibody binding.
Statistical analysis. Calculations were performed with
SPSS for Windows, version 10.0, statistical software (SPSS,
Chicago, Ill). Differences between data for patients and
control subjects were analyzed with the Mann-Whitney U
test. P .05 was considered significant. Values greater than
3 SD from the mean were excluded to avert the influence of
artifactual platelet activation.
RESULTS
Study population. One hundred persons were re-
cruited for the study. Mean age was 52.7 years for control
subjects, 66.6 years for patients with claudication, and 74.5
years for patients with critical ischemia. Sex distribution,
smoking habits, and mean ABI for the study population are
shown in the Table.
P-selectin expression. Percentage of platelets ex-
pressing P-selectin was significantly higher in patients with
intermittent claudication (median, 0.85%; range, 0.31%-
4.77%; P  .023) and critical ischemia (median, 1.11%;
range, 0.2%-3.26%; P  .028) compared with control
subjects (median, 0.59%; range, 0.16%-4.58%). These dif-
ferences were still significant when the only extreme value
was included in the analysis (claudication group, no
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change; critical ischemia group, no change; control group,
median, 0.6%, range, 0.16%-12.9%; P.039 and P .045,
respectively). Results for P-selectin expression are shown in
Fig 1. Median P-selectin mean fluorescence intensity was
1.585 for control subjects, 1.44 for patients with claudica-
tion, and 1.505 for patients with critical ischemia. There
was no difference in mean fluorescence intensity between
the three groups. Although percentage of platelets express-
ing P-selectin was higher in patients with critical ischemia
compared with patients with claudication, the difference
was not statistically significant.
Bound fibrinogen. Percentage of platelets binding
fibrinogen was significantly higher in patients with inter-
mittent claudication (median, 2.895%; range, 1.08%-
9.59%) compared with control subjects (median, 1.57%;
range, 0.17%-10.7%; P  .001). This difference was still
highly significant when the five extreme values were in-
cluded in the analysis (claudication group, median, 2.9%,
range, 1.08%-78.3%; control group, median, 1.58%; range,
0.17%-76.3%; P .001). However, there was no significant
difference between percentage of platelets binding fibrino-
gen in patients with critical ischemia (median, 1.3%; range,
0.09%-8.27%) compared with control subjects (P  .45).
Results of fibrinogen binding to platelets in the three
groups is shown in Fig 2. Median bound fibrinogen mean
fluorescence intensity was 2.75 for control subjects, 2.55
for patients with claudication, and 2.355 for patients with
Patient characteristics
Control subjects
(N  40)
Patients with
claudication (N  40)
Patients with critical
ischemia (N  20)
N % N % N %
Age (y)
Mean 52.7 66.6 74.5
Range 24-79 43-80 63-80
Sex
Male 16 40 34 85 12 60
Female 24 60 6 15 8 40
Smoking history
Smoker 10 25 13 32.5 8 40
Stopped smoking 1 y 0 8 20 2 10
Stopped smoking 1 y 15 37.5 14 35 8 40
Never stopped 15 37.5 5 12.5 2 10
Ankle-brachial pressure index 0.95 0.60 0.46
Fig 1. Scatterplot of percentage platelet P-selectin (Psel) expres-
sion in control subjects, patients with claudication, and patients
with critical ischemia. Horizontal lines, median values; one extreme
value has been excluded.
Fig 2. Percentage platelet bound fibrinogen (Fib) in control
subjects, patients with claudication, and patients with critical isch-
emia. Horizontal lines, median values; five extreme values have
been excluded.
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critical ischemia. On ex vivo stimulation of platelets with
ADP, patients with critical ischemia exhibited significantly
diminished platelet fibrinogen binding (median, 67.15%;
range, 1.52%-89.8%) compared with control subjects (me-
dian, 77.95%; range, 8.63%-97.6%; P  .006) (Fig 3).
There was no difference between control subjects and
patients with claudication (median, 78.3%; range, 18.6%-
97.6%; P  .31) in platelet fibrinogen binding after stimu-
lation with ADP.
DISCUSSION
The increased incidence of major vascular events in
patients with PAD and the central role of platelets in these
events raise the question of whether platelets in these
patients circulate in a “primed” or activated state. We found
a significantly higher percentage of platelets expressing
P-selectin in patients with PAD compared with control
subjects. In addition, the proportion of platelets binding
fibrinogen in patients with intermittent claudication was
significantly higher than in control subjects. There was,
however, no difference in resting platelet fibrinogen bind-
ing between control subjects and patients with critical
ischemia.
Flow cytometric studies of platelet activation in patients
with PAD have yielded conflicting results.12,13 Only the
study by Galt et al12 used percentage platelet expression of
P-selectin as a platelet activation marker. Those authors
found no difference in percentage platelet P-selectin ex-
pression between 15 control subjects and 16 patients with
severe PAD. However, the technique used for sample prep-
aration involved significant blood handling, which inevita-
bly results in excessive platelet activation in vitro. Indeed,
the results obtained by Galt and colleagues for percentage
of platelets expressing P-selectin (11% for patients with
PAD, 13% for control subjects) is more than 10-fold higher
than those obtained in our study. Other researchers using
flow cytometric analysis of P-selectin expression in patients
with stroke21 and coronary heart disease22 have reported
percentage platelet expression between 0.35 and 4.7, sim-
ilar to our figures. Use of whole blood flow cytometry of
platelets minimizes the contribution of in vitro activation
and may reflect more closely the in vivo condition. Extreme
care was taken during blood sampling and processing to
minimize blood handling and artifactual platelet activation.
Koksch et al13 used an improved technique for flow
cytometric analysis of platelet activation. They found that
P-selectin expression on both ADP-stimulated and nonstimu-
lated platelets was significantly increased in patients with PAD
compared with control subjects. However, that group re-
ported only fluorescence intensity of platelets rather than
actual percentage of activated platelets in the peripheral circu-
lation, and their conclusions were based on these measure-
ments. Mean fluorescence intensity alone is not a realistic
reflection of proportion of activated platelets in the circula-
tion, because it is simply a measure of the mean quantity of
antibody bound to each platelet, and in our study no differ-
ence was noted between the three groups. The control sub-
jects in the study by Koksch et al13 were younger than the
patients with PAD, as was also the case in our study. Platelet
function and coagulation activity, however, are independent
of age,23 and differences in mean age between groups should
not have significantly affected results. Our goal was to find
control subjects who were as close to the study groups as
possible, yet did not have evidence of arterial disease. Percent-
age of patients who smoked was similar in all groups. Smoking
increases platelet activation.
All patients with PAD in the study were receiving low-
dose aspirin therapy (75-150 mg); none of the control sub-
jects had been taking aspirin. Aspirin does not appear to
influence platelet P-selectin expression and fibrinogen binding
in healthy control subjects,24 and it is also noteworthy from
our results that aspirin alone is insufficient to completely
suppress in vivo platelet activation in patients with PAD. While
there is considerable overlap in values between PAD and
control groups, measurement of platelet activation may allow
individual patient- directed antiplatelet therapy in the future.
More effective anti-platelet treatment strategies, including
newer anti-platelet drugs and combinations of drugs, may be
more effective in achieving this. We are currently investigating
the effect of the combination of aspirin and clopidogrel in
patients with claudication undergoing peripheral angioplasty,
in a randomized controled trial.
Platelet fibrinogen binding increased with ADP stimu-
lation in both control subjects and patients with PAD.
There was no difference between ADP-stimulated platelet
fibrinogen binding between control subjects and patients
with claudication. However, ADP-stimulated platelet fi-
brinogen binding was significantly less in patients with
critical ischemia compared with control subjects. This sug-
gests that platelets from patients with critical ischemia are
Fig 3. Percentage platelet bound fibrinogen at adenosine triphos-
phate stimulation (ADP Stim) in control subjects, patients with
claudication, and patients with critical ischemia. Horizontal lines,
median values.
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less responsive to in vitro stimulation. This has also been
shown by Galt et al,12 whose patients all had severe PAD
with ABI below 0.45, which would match our group of
patients with critical ischemia. Reduced platelet responsive-
ness to stimulation has also been found in patients who
have had atherothrombotic stroke.21 One possible expla-
nation for these findings is that, as a result of removal from
the circulation of those activated platelets that have formed
platelet-platelet and platelet-leukocyte aggregates, the re-
maining circulating platelets are less susceptible to stimula-
tion. In other words, the platelet population is made up of
subpopulations of platelets with a different propensity for
activation. In patients with severe PAD those platelet
groups that are more easily activated will be removed from
the circulation as they adhere and aggregate at sites of
diseased endothelium, leaving those platelets that are less
responsive in circulation and platelets that have already
been activated and are no longer susceptible to further
stimulation. The failure of platelets in patients with critical
ischemia to demonstrate increased fibrinogen binding is
difficult to explain and requires further study.
This finding highlights the problem with sampling of
peripheral blood to assess platelet activation. Although we
used whole blood flow cytometry and were extremely care-
ful to standardize preanalytical procedures (blood with-
drawal, specimen handling, exact and frequent instrument
calibration) to avert artifactual platelet stimulation, the
study assessed function in circulating platelets. This does
not necessarily reflect activity of platelets at the site of
atherosclerotic plaque throughout the vascular system, and
therefore it is only an indirect assessment of platelet func-
tion. Attempts have been made to assess platelet function at
the site by measuring platelet activation in arterial blood
taken distal to lesions treated at angioplasty through an
arterial catheter.25 This may introduce artifact from platelet
activation induced by the procedure itself.
In conclusion, our study provides evidence for enhanced
platelet activation in patients with PAD. Platelet activation is a
marker of a prothrombotic state, which may be partly respon-
sible for the increased incidence of major vascular events and
disease progression in this group of patients.
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